ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure
- PMID: 30657875
- PMCID: PMC6383054
- DOI: 10.1093/cvr/cvz010
ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure
Abstract
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and are increasing worldwide. Patients with IHD or HF might benefit from novel therapeutic strategies, such as cell-based therapies. We recently discussed the therapeutic potential of cell-based therapies and provided recommendations on how to improve the therapeutic translation of these novel strategies for effective cardiac regeneration and repair. Despite major advances in optimizing these strategies with respect to cell source and delivery method, the clinical outcome of cell-based therapy remains unsatisfactory. Major obstacles are the low engraftment and survival rate of transplanted cells in the harmful microenvironment of the host tissue, and the paucity or even lack of endogenous cells with repair capacity. Therefore, new ways of delivering cells and their derivatives are required in order to empower cell-based cardiac repair and regeneration in patients with IHD or HF. Strategies using tissue engineering (TE) combine cells with matrix materials to enhance cell retention or cell delivery in the transplanted area, and have recently received much attention for this purpose. Here, we summarize knowledge on novel approaches emerging from the TE scenario. In particular, we will discuss how combinations of cell/bio-materials (e.g. hydrogels, cell sheets, prefabricated matrices, microspheres, and injectable matrices) combinations might enhance cell retention or cell delivery in the transplantation areas, thereby increase the success rate of cell therapies for IHD and HF. We will not focus on the use of classical engineering approaches, employing fully synthetic materials, because of their unsatisfactory material properties which render them not clinically applicable. The overall aim of this Position Paper from the ESC Working Group Cellular Biology of the Heart is to provide recommendations on how to proceed in research with these novel TE strategies combined with cell-based therapies to boost cardiac repair in the clinical settings of IHD and HF.
Keywords: Biomaterials; Cardiac tissue engineering; Cells; Heart failure; Ischaemic heart disease.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.Eur Heart J. 2016 Jun 14;37(23):1789-98. doi: 10.1093/eurheartj/ehw113. Epub 2016 Apr 7. Eur Heart J. 2016. PMID: 27055812 Free PMC article. Review.
-
Recent advancements in tissue engineering for stem cell-based cardiac therapies.Ther Deliv. 2013 Apr;4(4):503-16. doi: 10.4155/tde.13.13. Ther Deliv. 2013. PMID: 23557290 Review.
-
Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy.Adv Drug Deliv Rev. 2010 Jun 15;62(7-8):784-97. doi: 10.1016/j.addr.2010.03.001. Epub 2010 Mar 6. Adv Drug Deliv Rev. 2010. PMID: 20214939 Review.
-
Cellular Therapy for Ischemic Heart Disease: An Update.Adv Exp Med Biol. 2019;1201:195-213. doi: 10.1007/978-3-030-31206-0_10. Adv Exp Med Biol. 2019. PMID: 31898788 Review.
-
Application of injectable hydrogels for cardiac stem cell therapy and tissue engineering.Rev Cardiovasc Med. 2019 Dec 30;20(4):221-230. doi: 10.31083/j.rcm.2019.04.534. Rev Cardiovasc Med. 2019. PMID: 31912713 Review.
Cited by
-
Inducing positive inotropy in human iPSC-derived cardiac muscle by gene editing-based activation of the cardiac α-myosin heavy chain.Sci Rep. 2024 Feb 16;14(1):3915. doi: 10.1038/s41598-024-53395-4. Sci Rep. 2024. PMID: 38365813 Free PMC article.
-
Study of the effect of keap1 on oxidative stress in human umbilical cord mesenchymal stem cells.Mol Biol Rep. 2024 Jan 3;51(1):67. doi: 10.1007/s11033-023-08997-y. Mol Biol Rep. 2024. PMID: 38170368 Free PMC article.
-
Cell Therapy in the Treatment of Coronary Heart Disease.Int J Mol Sci. 2023 Nov 28;24(23):16844. doi: 10.3390/ijms242316844. Int J Mol Sci. 2023. PMID: 38069167 Free PMC article. Review.
-
The progress of autoimmune hepatitis research and future challenges.Open Med (Wars). 2023 Oct 30;18(1):20230823. doi: 10.1515/med-2023-0823. eCollection 2023. Open Med (Wars). 2023. PMID: 38025543 Free PMC article. Review.
-
Stem cell-based therapies for heart failure management: a narrative review of current evidence and future perspectives.Heart Fail Rev. 2023 Sep 21. doi: 10.1007/s10741-023-10351-0. Online ahead of print. Heart Fail Rev. 2023. PMID: 37733137 Review.
References
-
- A futile cycle in cell therapy. Nat Biotechnol 2017;35:291.. - PubMed
-
- Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery CL, Janssens S, Willerson J, Eschenhagen T, Ferdinandy P, Sluijter JPG.. Position paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J 2016;37:1789–1798. - PMC - PubMed
-
- Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JCTACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) Writing Group; Authors/Task Force Members. Chairpersons; Basic Research Subcommittee; Translational Research Subcommittee; Challenges of Cardiovascular Regenerative Medicine Subcommittee; Tissue Engineering Subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee; Clinical Trials Subcommittee; Regulatory and funding strategies subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee.. Global position paper on cardiovascular regenerative medicine. Eur Heart J 2017;38:2532–2546. - PMC - PubMed
-
- Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisén J, Giacca M, Hare JM, Houser S, Lee RT, Marbán E, Martin JF, Molkentin JD, Murry CE, Riley PR, Ruiz-Lozano P, Sadek HA, Sussman MA, Hill JA.. Cardiomyocyte regeneration: a consensus statement. Circulation 2017;136:680–686. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
